From LBP, “The Jerome Lejeune Foundation has been developing therapeutic treatments related to the overexpression of the gene Dryk1A (implicated for causing intellectual disability) for those living with Down syndrome. Clinical trials of interest to us include the use of EGCG, a natural substance found in green tea, as an inhibitor of Dryk1A. They have just announced a new partnership with Manros Therapeutics to develop a new drug from a molecule described in scientific literature as the most powerful inhibitor of Dryk1A.”
By mbradford | lejeuneusa.org
The Jerome Lejeune Foundation has been intensely involved in supporting the development of therapeutic treatments related to the overexpression of the gene Dryk1A for those living with Down syndrome.